Volume continues to be above avg. With stock moving higher and new short positions replacing our old JAZZ shorts, JAZZ remains at a fair market price. I predict the stock will be in the 70's before next earnings are announced and I anticipate short covering into the high 70's to low 80's.
I am both happy and amused at the volume of repetitive unprofessional posters I see on this board showing just how nervous and frightened they are as we begin the next 30 point rise.
3 cheers for all the investors who can look forward to holding JAZZ for another 3 years. I predict within 36 months JAZZ will initiate a cash dividend program. This will come about after several stock splits.
Jazz Pharmaceuticals Gains on Xyrem Court Ruling
12:41p ET September 17, 2012 (Dow Jones) Jazz Pharmaceuticals Gains on Xyrem Court Ruling
Shares of Jazz Pharmaceuticals PLC (JAZZ) jumped 13.2% to $54.47 recently following news that a federal court has issued a Markman ruling largely in favor of Jazz on its narcolepsy medication Xyrem.
"The judge in the Xyrem patent case just issued the long awaited Markman ruling that defines the patent claim terms," wrote Jefferies analyst Corey Davis in his note Monday.
"In our initial read, we count 17 occurrences of agreeing with the Jazz construction and zero occurrences of agreement with Roxane [Laboratories]. We have not had a chance to fully review the 43 page ruling, but at first blush this seems like a clear win for Jazz," Davis added.
Jazz's stock has climbed approximately 12% over the past 30 days and over 41% year-to-date.